Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals to $342 from $313 and keeps an Overweight rating on the shares post the Q4 results. The analyst continues to see the cystic fibrosis franchise supporting a "floor value" with Vertex’s pipeline assets providing additional upside.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals board authorizes $3.0B buyback
- Vertex Pharmaceuticals reports Q4 EPS $3.76, consensus $3.51
- Vertex options imply 3.7% move in share price post-earnings
- Vertex keeps cystic fibrosis drug out of developing countries, NY Times reports
- Vertex Pharmaceuticals price target raised to $296 from $293 at Piper Sandler
